ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

According to results from the phase III phase III LyMa trial published in the New England Journal of Medicine, survival was improved for patients with mantle cell lymphoma with maintenance rituximab (Rituxan) following autologous stem-cell transplantation (ASCT).

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.